<DOC>
	<DOC>NCT01810627</DOC>
	<brief_summary>This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.</brief_summary>
	<brief_title>Application of Megavoltage Imaging to Reduce Artifact After Seed Implants</brief_title>
	<detailed_description />
	<criteria>Male 5080 years of age Eligible for interstitial brachytherapy implants</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
</DOC>